Using Novilase Laser Therapy to Treat Small Breast Tumors

Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)

This study is testing whether Novilase laser therapy can effectively treat small breast tumors and help more people avoid traditional surgery.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 122 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: Novian Health Inc. (Industry-sponsored)
• Drugs / interventions: radiation
• Locations: 13 sites (Duarte, California and 12 other locations)
• Trial ID: NCT03463954 on ClinicalTrials.gov

What this trial studies

This clinical evaluation focuses on the effectiveness of Novilase laser therapy for the focal destruction of malignant breast tumors measuring 15 mm or less. Participants will undergo a screening MRI, followed by a laser ablation procedure, and will be monitored with an MRI and excision at 4-6 weeks post-treatment. The study aims to demonstrate that Novilase can achieve a complete tumor ablation rate exceeding 87.85%, compared to the standard lumpectomy procedure. This pivotal study builds on previous findings where 98% of similar tumors were successfully ablated in one session.

Who should consider this trial

Good fit: Ideal candidates are females aged 18 and older with unifocal malignant breast tumors that do not exceed 15 mm in size.

Not a fit: Patients with larger tumors or those with multifocal malignancies may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could provide a less invasive treatment option for patients with small malignant breast tumors.

How similar studies have performed: Previous studies have shown high success rates with similar laser ablation techniques, indicating potential for this approach.

Eligibility criteria

Inclusion Criteria:

* Females, aged 18 years and older
* Able to give written informed consent herself
* Definitive pathologic diagnosis by needle core biopsy
* Unifocal malignant tumor (T1a-c, N0-1, M0) that does not exceed 15 mm in longest dimension and measures at least 5 mm away from the skin and chest wall, or can be moved at least 5 mm away from the skin and chest wall by injection of saline or local anesthetic
* No more than 10 mm of calcifications confined to the tumor on imaging
* Tumor is well visualized through ultrasound or x-ray mammography imaging and amenable to image-guidance therapy (i.e., a tumor which is well visualized through imaging can be identified from surrounding breast tissue and does not have margins obscured by other structures or artifacts on the images)
* Tumor is well visualized on MRI
* Subject with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor site
* Tumor with less than 25% intraductal component, as determined by core biopsy
* No clinically significant co-morbidities (e.g., chronic illnesses existing simultaneously with and usually independent of breast cancer) that affect life expectancy
* Subject weight limited to ≤300 lbs. or ≤136 kg
* Subject agrees to comply with standard of care radiation or adjuvant therapy as prescribed by physician

Exclusion Criteria:

* Subject younger than 18 years of age
* Pregnant or breast-feeding
* Tumor poorly visualized by ultrasound or x-ray mammography imaging
* Contraindications to administration of gadolinium-based contrast agent, including: prior allergic reaction to a gadolinium-based contrast agent, moderate to end-stage kidney disease, and/or acute or chronic severe renal insufficiency (Glomerular filtration rate (GFR) \<30ml/min/1.73 sq. meters)
* Contraindications to MRI according to site guidelines (e.g., cardiac pacemaker, metallic implants)
* History of severe asthma
* Tumor measuring greater than 15 mm in longest dimension
* Microcalcifications that extend beyond target tumor such that overall longest dimension of target tumor and calcifications is longer than 15 mm.
* Advanced stage breast cancer
* Tumors that are lobular neoplasm, metastatic carcinoma to breast, sarcoma, Phyllodes tumor, or Paget's disease
* Tumor with only DCIS with microinvasion
* Extensive intraductal component in lesion (i.e., \>25%) as determined by core biopsy
* Subject who is known to be BRCA positive
* Tumor that is ER/PR/HER2 negative (TNBC)
* Inability to lie in prone or supine position for one hour
* Subject who is currently participating in another investigational treatment, device or drug study through follow up that would interfere with this trial
* Subject without a definitive HER2 test according to ASCO/CAP guidelines

Where this trial is running

Duarte, California and 12 other locations

• City of Hope — Duarte, California, United States (Withdrawn)
• UC San Diego Health — La Jolla, California, United States (Recruiting)
• Eisenhower Health — Rancho Mirage, California, United States (Recruiting)
• Yale University — New Haven, Connecticut, United States (Recruiting)
• Walter Reed National Military Medical Center — Bethesda, Maryland, United States (Withdrawn)
• Summit Health — Florham Park, New Jersey, United States (Not_yet_recruiting)
• Buffalo General Medical Center — Buffalo, New York, United States (Recruiting)
• St. Elisabeth-Krankenhaus Köln-Hohenlind — Cologne, Germany (Recruiting)
• Ichilov | Tel Aviv Sourasky Medical Center — Tel Aviv, Israel (Recruiting)
• Breast Centre Zurich — Zurich, Switzerland (Terminated)
• University Hospital Zurich — Zurich, Switzerland (Recruiting)
• Charing Cross Hospital, Imperial College Healthcare NHS Trust — London, United Kingdom (Recruiting)
• Churchill Hospital, Oxford University Hospitals NHS Trust — Oxford, United Kingdom (Recruiting)

Study contacts

• Principal investigator: John Lewin, MD — Yale University
• Study coordinator: Eugene Bajorinas

Conditions Malignant Neoplasm of Breast; less than or equal to 15 mm